Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?
- PMID: 18682771
- PMCID: PMC2494892
- DOI: 10.5489/cuaj.602
Why consider neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder?
Comment on
- Can Urol Assoc J. 2:229.
References
-
- Canadian Cancer Society. 2007 Cancer Statistics. Available: www.cancer.ca (accessed 2007 Nov 15).
-
- Quek ML, Stein JP, Nichols PW, et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005;174:103-6. - PubMed
-
- Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium — efficacy and patterns of response and relapse. Cancer 1989;64:2448-58. - PubMed
-
- Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumours. J Clin Oncol 1990;8:1050-5. - PubMed
-
- von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus MVAC in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77. - PubMed
LinkOut - more resources
Full Text Sources